Latest Market Access News

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.

Carnaby Resources has completed the settlement of Tranche 2 of its recent share placement, issuing 13.5 million new shares to raise approximately $4.2 million, including participation from its board members.

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.

Cardiex has kicked off deliveries of its CONNEQT Pulse arterial health monitors in the U.S., reporting strong preorder momentum and a 150% sales increase in December. The company’s strategic operational shifts and pharma partnerships set the stage for sustained growth in 2025.

Red Sky Energy's December 2024 report reveals steady production from Yarrow 3, imminent fracture stimulation at Yarrow 1, and a transformative 35% stake in Angola's Block 6/24, positioning the company for diversified growth and enhanced cash flow.

Elsight reported a robust 32% increase in annual revenue for 2024, driven by a strategic pivot towards the defense sector, which now accounts for over half of its total revenue. The company’s expanding customer base and debt elimination position it well for growth in 2025.

Echo IQ confirms the material significance of its pre-submission FDA meeting for EchoSolv HF, marking a pivotal step toward US market entry and commercialisation.

Cokal Limited has strengthened its position in Central Kalimantan through strategic partnerships with PT Petrindo and Cratus Group, securing US$20 million in funding to boost coal production and infrastructure development.

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.